Dachaigh › Luchd-obrach › Janssen Global Services, LLC
Janssen Global Services, LLC: Tuarastalan H-1B agus taic bhìosa
Chuir Janssen Global Services, LLC 16 iarrtasan cumha-obrach a-steach airson bhìosaichean H-1B agus bhìosaichean co-cheangailte ann am bliadhnaichean ionmhais 2023–2026; le teisteanas: 16. Tuarastal meadhanach a chaidh a thabhann: $242,200.
A bheil Janssen Global Services, LLC a’ toirt taic do bhìosaichean H-1B?
Chuir Janssen Global Services, LLC 16 iarrtasan cumha-obrach a-steach ann am bliadhnaichean ionmhais 2023–2026, an tè as ùire air a chur a-steach air 16 Ògmh 2026. Is e LCA a’ chiad cheum ann an iarrtas H-1B, mar sin tha an neach-fastaidh air taic a thoirt do luchd-obrach H-1B no air ullachadh airson sin a dhèanamh; cha gharantaich e taic airson dreuchd shònraichte sam bith. Thoir sùil air liostaichean obrach an neach-fastaidh fhèin.
Tuarastalan a rèir tiotal obrach
| Tiotal dreuchd | LCAs | Tuarastal meadhanach |
|---|---|---|
| Senior Director Transactions Immunology, Acquisitions | 2 | $312,600 |
| Associate Director, Global Market Access Oncology | 1 | $197,400 |
| Associate Director, Health Economics Modeling | 1 | $190,000 |
| Director, Global Commercial Strategy | 1 | $248,900 |
| Senior Director, Transactions Immunology and Acquisitions | 1 | $312,300 |
| Director Global Comm Strat Precision Medicine | 1 | $174,699 |
| Associate Director, Global Real World Evidence (RWE) | 1 | $190,000 |
| Head of Market Access, Oncology | 1 | $372,000 |
| Director, Alliance Management | 1 | $235,500 |
| Manager, Global RWE - Immunology | 1 | $180,000 |
| Manager, Global RWE - Oncology | 1 | $170,000 |
| Director, Global Medical Affairs Lead | 1 | $250,000 |
| Senior Principal Data Scientist Global Data Science | 1 | $211,100 |
| Medical Director Oncology Hematology | 1 | $266,200 |
| VP, Therapeutic Area Market Access Leader, Oncology | 1 | $390,700 |
Iarrtasan a rèir bliadhna ionmhais
| Bliadhna mhaoine | LCAs | Tuarastal meadhanach |
|---|---|---|
| FY2024 | 5 | $248,900 |
| FY2025 | 4 | $212,750 |
| FY2026 | 7 | $250,000 |
Ìrean tuarastail làithreach
Suidhichidh Roinn an Obrach ceithir ìrean tuarastail làithreach airson gach dreuchd agus sgìre, bho Ìre I (inntrigeadh) gu Ìre IV (gu tur comasach). Taghaidh an neach-fastaidh an ìre a fhreagras ri riatanasan na h-obrach.
Far a bheil na h-obraichean
Dreuchdan
- Medical and Health Services Managers3
- Marketing Managers3
- Financial Managers3
- Epidemiologists2
- Molecular and Cellular Biologists1
- Statisticians1
- Medical Scientists, Except Epidemiologists1
- Natural Sciences Managers1
- Data Scientists1
Iarrtasan as ùire
| Tiotal dreuchd | Tuarastal bunasach | Àite | Air a chur a-steach | Ceann-latha tòiseachaidh | Inbhe |
|---|---|---|---|---|---|
| VP, Therapeutic Area Market Access Leader, Oncology | $390,700 E-3 · Ìre IV | Raritan, NJ | 16 Ògmh 2026 | 20 Lùna 2026 | Dearbhaichte |
| Medical Director Oncology Hematology | $266,200 Ìre IV | Raritan, NJ | 5 Ògmh 2026 | 1 Dàmh 2026 | Dearbhaichte |
| Senior Principal Data Scientist Global Data Science | $211,100 Ìre IV | Raritan, NJ | 28 Cèit 2026 | 1 Dàmh 2026 | Dearbhaichte |
| Director, Global Medical Affairs Lead | $250,000 Ìre IV | Raritan, NJ | 5 Cèit 2026 | 1 Dàmh 2026 | Dearbhaichte |
| Senior Director Transactions Immunology, Acquisitions | $322,000 E-3 · Ìre IV | New Brunswick, NJ | 26 Dùbh 2025 | 7 Ògmh 2026 | Dearbhaichte |
| Manager, Global RWE - Oncology | $170,000 Ìre III | Raritan, NJ | 5 Samh 2025 | 25 Samh 2025 | Dearbhaichte |
| Manager, Global RWE - Immunology | $180,000 Ìre III | Raritan, NJ | 5 Samh 2025 | 17 Samh 2025 | Dearbhaichte |
| Director, Alliance Management | $235,500 Ìre IV | Titusville, NJ | 15 Sult 2025 | 1 Samh 2025 | Dearbhaichte |
| Director Global Comm Strat Precision Medicine | $174,699–$285,000 Ìre IV | Raritan, NJ | 20 Dùbh 2024 | 2 Cèit 2025 | Dearbhaichte |
| Associate Director, Global Real World Evidence (RWE) | $190,000 Ìre III | Raritan, NJ | 5 Dùbh 2024 | 16 Dùbh 2024 | Dearbhaichte |
| Head of Market Access, Oncology | $372,000 E-3 · Ìre IV | Raritan, NJ | 30 Sult 2024 | 15 Dàmh 2024 | Dearbhaichte |
| Senior Director, Transactions Immunology and Acquisitions | $312,300 E-3 · Ìre IV | New Brunswick, NJ | 5 Gibl 2024 | 8 Iuch 2024 | Dearbhaichte |
| Director, Global Commercial Strategy | $248,900 E-3 · Ìre III | Raritan, NJ | 5 Gearr 2024 | 10 Gibl 2024 | Dearbhaichte |
| Senior Director Transactions Immunology, Acquisitions | $303,200 E-3 · Ìre IV | New Brunswick, NJ | 5 Faoi 2024 | 20 Cèit 2024 | Dearbhaichte |
| Associate Director, Global Market Access Oncology | $197,400 Ìre IV | Raritan, NJ | 4 Dùbh 2023 | 25 Cèit 2024 | Dearbhaichte |
| Associate Director, Health Economics Modeling | $190,000 Ìre III | Raritan, NJ | 28 Samh 2023 | 11 Dùbh 2023 | Dearbhaichte |
Is e na tuarastalan an ìre as ìsle den tuarastal a chaidh a thabhann air gach iarrtas, air an tionndadh gu suim bhliadhnail; cleachdaidh na staitistigean iarrtasan làn-aimsire le teisteanas a-mhàin. Chan eil LCA na aontachadh bhìosa agus faodaidh aon LCA còmhdach a dhèanamh air iomadh dreuchd. Stòr: Roinn an Obrach na SA, Dàta Foillseachaidh OFLC LCA, bliadhnaichean ionmhais 2023–2026 (co-dhùnadh as ùire 30 Ògmh 2026).